a company with global vision - beacon pharmaceuticals limited€¦ · created date 6/1/2016 3:42:42...

6
BEACON PHARMACE'UTICALS LTD. 153-L54 Teigoan uA., Dhaka -1208 S.-if"Ti i u; E !t -:" O * E ! f\: A ll Cl AL P /' ilTl O N ( U n-a u al it ^ d ) r"" at lilst lVri, , 2U74 31-Mar-14 Particulars ASSETS Non-Current Assets: Property, Plant & Equipments Capital Work in Progress Deferred IPO Expense Total Non-Current Assets Current Assets: lnventories Accounts Receivable Advance, Deposit & Pre-PaYments Cash & Cash Equivalants Total Current Assets lnvestment: lnvestment Totallnvestment TOTAL ASSETS sHaRrHotorRs' rQultY & ttAgttlfles Shareholders' Equity: Paid up Capital Reserve and Surplus 'Retaines Earning Totat Shareholders' EquitY Non-Current Liabi Iities: Long Term Loan: Current Liabilities: Liabilities for EWF & WPPF ShortTerm Loan Current Portion of Long Term Loan Share Application Money Refundable Accounts Payable Tax Payable Accrued Expense Vat Payable Total Current Liabilities TOTAL SHAREHOLDERS' EQUITY & LIABITITIES Net Asset value (NAV) / Share Par Value(Tk.) 2,432,223,189 199,L99,97L L0,652,455 2,642,075,625 Amount in Tk. 30-Jun-13 2,55O,O94,661 880,923 L4,203,289 2,565,L18,873 991,69L,827 tzo,298,4O8 524,323,9L2 4,626,408 1,640,940,555 920,497,4V5 157,859,545 44O,43O,LOs 7,673,698 1,526,460,823 c 318,895,565 318,895,555 L59,980,190 159,980,190 4,6OL,91L,745 4,251,6L9,886 2,3L0,000,000 323,259,263 1.47.236.860 2,780,496,123 2,31.0,000,000 336,552,059 126,706,269 2,773,258.328 591 69t,822,502 776,0t3,169 776,OL3,L69 L5,727,636 970,138,901 3L,884,784 4,956,614 77,645,306 64,075,777 23,767,849 L,396,253 L,129,593,LzO 4,601,9L1,745 t2.04 10.00 4,251",6L9,886 12.01 10.00 74,869,7L2 512,496,894 63,584,240 4,956,614 20,837,254 60,362,027 24,512,591 629.057 702.348.389 o, Company Secrb [w^-f, M'anaging Director

Upload: others

Post on 10-Aug-2020

0 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: A Company With Global Vision - Beacon Pharmaceuticals Limited€¦ · Created Date 6/1/2016 3:42:42 PM

BEACON PHARMACE'UTICALS LTD.

153-L54 Teigoan uA., Dhaka -1208

S.-if"Ti i u; E !t -:"

O * E

! f\: A ll Cl AL P /' ilTl O N ( U n-a u al it ^ d )

r"" at lilst lVri, , 2U74

31-Mar-14ParticularsASSETS

Non-Current Assets:

Property, Plant & Equipments

Capital Work in Progress

Deferred IPO Expense

Total Non-Current Assets

Current Assets:

lnventoriesAccounts Receivable

Advance, Deposit & Pre-PaYments

Cash & Cash Equivalants

Total Current Assets

lnvestment:lnvestmentTotallnvestment

TOTAL ASSETS

sHaRrHotorRs' rQultY & ttAgttlflesShareholders' Equity:

Paid up Capital

Reserve and Surplus'Retaines Earning

Totat Shareholders' EquitY

Non-Current Liabi Iities:

Long Term Loan:

Current Liabilities:

Liabilities for EWF & WPPF

ShortTerm Loan

Current Portion of Long Term Loan

Share Application Money Refundable

Accounts Payable

Tax Payable

Accrued Expense

Vat Payable

Total Current LiabilitiesTOTAL SHAREHOLDERS' EQUITY &LIABITITIES

Net Asset value (NAV) / Share

Par Value(Tk.)

2,432,223,189

199,L99,97L

L0,652,4552,642,075,625

Amount in Tk.

30-Jun-13

2,55O,O94,661

880,923

L4,203,289

2,565,L18,873

991,69L,827

tzo,298,4O8524,323,9L2

4,626,408

1,640,940,555

920,497,4V5

157,859,545

44O,43O,LOs

7,673,698

1,526,460,823

c318,895,565

318,895,555

L59,980,190

159,980,190

4,6OL,91L,745 4,251,6L9,886

2,3L0,000,000

323,259,2631.47.236.860

2,780,496,123

2,31.0,000,000

336,552,059

126,706,269

2,773,258.328

591

69t,822,502

776,0t3,169776,OL3,L69

L5,727,636

970,138,901

3L,884,784

4,956,614

77,645,306

64,075,777

23,767,849

L,396,253

L,129,593,LzO

4,601,9L1,745

t2.0410.00

4,251",6L9,886

12.01

10.00

74,869,7L2

512,496,894

63,584,240

4,956,614

20,837,254

60,362,027

24,512,591629.057

702.348.389

o,Company Secrb

[w^-f,M'anaging Director

Page 2: A Company With Global Vision - Beacon Pharmaceuticals Limited€¦ · Created Date 6/1/2016 3:42:42 PM

l1Jlorlald

IPlolla

s :a i3HiEl[iil 3ptaila[1E...-- ;4 q<\\Ps6HE'*o i i gi ts qi { *iP iFi*iE\U xEa qEsaI E t 3[ AE\ E ia6n; ' n tsE d

Olt?-o96B

\rl

o,UJ r-O. '5.

8s6E

PF

b'ur =- lDa -*EP 6liE 3l=:6 Pl+

Hr'ut

g

<uJ3s+3.q,

FF

PP(o(o5o(oNN)

(,(,tr.o

\tsso(.1)

!P

FoLAJbN)F(,@@

FjINro(l1oo

P(rlFl^)roNNtr)

P!I{(Jl(oF{{

c,'l(^lo!

NFCtl

UJPo{!(JlOlOl

P.(, -lJlil{

EFmq)rJN'.trO

Ntstt(oFrocrr

(rl{(obNJ5

tl

(,l@oFl\,

+:w5NOl{!*E h

ctoF-3IOHa:60,

F(1,

ll-sHi Et

FNulFF(Do(,r

u)lJt(,o@N)F

@5lor\) cn6rC){{[email protected]

ouru)Fc)

(rJ

t\)oON\t\o

(Jlq,u,q)

rt,00

ql@

iE* EcPA z1nE ?

EEE,IEF hH;E EEE B HHil,5'tre

E-.(DCL

F(o1\, N){F5N){olHPo{l{ {lo (,l)

P\,1OlolJlOl{qlqr

F(o(rl

(ooo(1,

l_N IOr\) lll,io Ii.,(o lNl. llep lOOI IPto IO

N)(o qlulP{5orF.!^, J-'I{\tol@\r{

HtsF@ololrowLIJ

u)ur

C')grrJt5

l-l\fl\rlurl6li-loIN

P(Jl{@NoCr){E

NoP

N

6roro

1,1=N

lilg slb lo oolor lI. Ln

Fr,Iu,ulu)

Pq,

(.l.,

so00(/IP!ul{

lJl(rlo(orI(r)

(,!1ol.J!@{{Ol

(,(JlroLNsooN\l(.^)

(r'lulFglu)(oo€

OlFo5lIN(Jl{

ts5PCX'

orults

!^,F5J\.,'(,(.r)(o

!'(.^)roa(,(Jt(o

5glCDo(o(oo

orrooo(1,Put

FP@(.r)

Cfiooo

rP00(^J

b'orc)

qtw

(1,@N

ultv{!H,NJ C'T

t9{NOFCD

POlI@N)@'

uu)NNOPol olNulour\I D

II

* [n., .,rtl'o bO IF FN IIJ F'6 l'o' bo l@ aF I}l N

Noou,F{

NUJt'ooo9i)OONO

N(,t'ooo9boo

FO

NUJt'ooo9booPO

\.1F@{{,oPNJ

ied{ENGlnoXo.lq

Page 3: A Company With Global Vision - Beacon Pharmaceuticals Limited€¦ · Created Date 6/1/2016 3:42:42 PM

I

T'0,

\

v'3@-rD m

fEESH=AZCL^ljloxt!c ct:r I} Tfr Ed s3 3a 3<. >PzDr.)f m j mEoo -3=il-3=il'6==Nt-t{B[nV^lll-*-log

P

tn

'nDo{imr!<l=o-op'ngero-f>gz!i Iivt!zEEtt- C

=lH=LEE4urd

CL

3og

{

3og

0,J0,E.0lloo.lo

or+q,

lt1 v1

HEiri(Dg'od<(,6-P=o_ o-

=.fga+ooo)a

-9o3oJ*o+r

5o+3of*+t-o,3-lO)x-go-o)

po(Ao?o

-l-o,Jli+(D-aoo-do-lox-gdo)

J

oto?o

voo)

o)*.ofvovtoaoqo)oEIt3o5

u1 >iJorD

o:(*

t-ov,li*ao:f+roIaoo-+rao35oo=o

!a.oa(Do)aoo-

att*3(D

+)(D

ooq9.

=J.aUq

oa5o(Do:

.oq,

e.(.!gil]n

Nu)

Ioooooo

a

N(, .)HoOOoooo

(

OJ

oa)0,E'0,

w

(,ror

cn5I

ts(,N)(oN)!(.oO)

a

(x(xPo59o(oO)o

vilaoc=go6'

J

grulol^,ororo

I 1

qt(Jlo(,A)

o(o(o

ilioo6S

P5NUJ(n00CNo

I

P(,Nr.oN.'\,1(oO)

!N)UJ!!(our

FN)ql!oIN)O)(o

7oq,

oo-mo,

J

='Gt

N6oA€INLD

!NU)!!(oUl

N){\l.(,N(/l.00LrJN.,@

ogm

.Ctg

a

r)o3

ogL

(A Vtqr53Eroo6od<ti|ao:J o-)o-qc

=.gq*=o

.oo)-!O,

JJo-o

f,o+3o)d+ro3-{TDx-gCLo,

vo@o:o

-{ao)

=thoaaoo-*o{o)x-gdo)

7(DlnoerD

voo,

o)t.of7olrtoeoo-o)o-tn

3o=t

vl 26i 6-O!

dqJ

l-oIAtt,

+ao)ft

oaaoq+r-o==oo)o

'o=.oaoIIJao)o.tit+3of

dt+oooq9.JJ3'uqo+rt)ooOJa

'o0,

a.ocai1h

r.

(F\?

r

Nu)

ooooooo

lv(xFoooooOO

ttl)0,

oo0,t0,

u)(^lurtrobr.oN

H(.1)

N)roN!rog)

UJ5@!!N)O)@@

7z93dtDc

=go6'f

lJlulou,o(oro

I

ul(,o(.^J

Oro(o

il1ooEF

650ooo'rro

F(,N.,(olv\t(oot

ulUJ(,L^){(o@

ror.0

@(Jlts5\t(n

f,og.

=otLmo

='Jt/Q

Ngr(o5(nFr()(no

I

ulU)(.^)(x!(o@

I

N!OlslJN){N)OlN)

o-gr

mltg

Page 4: A Company With Global Vision - Beacon Pharmaceuticals Limited€¦ · Created Date 6/1/2016 3:42:42 PM

iEACO0$ t':"*Ar't W f.rCE UTICALS LTn.L53-154 Tejgoan rf A., i;nalta-1208

STATEMENT OF CASH FLOW (Un-audited)

For the 3rd Quarter ended 31st March, 2014

July'13 toMar'14

9 Months

Amount in Tk.

July'12 toMar'13

9 MonthsParticulars

Cash Flows from Operating Activities:Collection against Sales

Payment to CreditorsOther Operating Expense

lnterest Paid

Received from other sources

Net Cash Generated from Operating Activities

(15,915,836)

(15,915,836)

dt N"tCash Generated from Financing Activities

TotalCash Flow

Cash and Cash Equivalent - Opening

Cash and Cash Equivalent - Closing

Operating Cash flow per Share

Nos. of Shares lssued

,r^rM

1a+,.[Jo,oal1425,842,551

341,651,884

(3,047,290)

7,673,699

4,626,4O9

0.13

231,000,000

L,236,97O,339

(404,369,653)

(664,468,2911

(L7O,759,477l,

32,077,56629,45O,485

9L7,186,4L2"(468,099,7771

(89,859,221)

(L3L,326,L77:)

4,223,633232,124,870

C a"rn Ftows from lnvesting ActivitiesAcquisition of Property, Plant & Equipments

lnvestment

lnterest and Other Received

Net Cash Generated from Investing Activities

Cash Flows from Financing ActivitiesCapitalReceivedDeferred IPO Expense

Excess Share Application Money Received

Excess Share Application Money Refund

Lbng Term Loan Received

LongTerm Loan Refund

Short Term Loan Received

ShortTerm Loan Refund

(2L5,234,2831

(158,915,375)

(374,L49,6581

(578,162)

(703,7L6,487l

(L09,464,225)

{213,758,8741

2,450,L617,202,594

9,652,745

1.00

231,000,000

Managing Director

Page 5: A Company With Global Vision - Beacon Pharmaceuticals Limited€¦ · Created Date 6/1/2016 3:42:42 PM

Notes to th,r,; EinaneiaN PmsitionFor the 3rd quqlter ended 31st Ma:.eh, 2014

1.00 Selected explanatory notes:The financial statements have been prepared in line with accounting policies as adoptedin the preparation of financial statements for the period ended 31st March, 2014. Thisinterim financial report includes those seleted explanatory notes as were deemedappropriate for the better understanding of the said un-audited financial statements.

2.00 Presentation of financial statements and basis of accounting:The financial statements have been prepared in accordance with Generally AcceptatedAccounting Principles under Historical Cost Convention and after compliance withBangladesh Financial Reporting Standard (BFRS) & Bangladesh Accounting Standard(BASs) adopted by the lnstitute of Chartered Accountants of Bangladesh (|CAB), theCompanies Act 1994, the Securities and Excxhange Rules 1987 and other applicablelaws and regulations.

3.00 Property, Plant & Equipment:3.01 Recognition and Measurement

Propefi, plant and equipment are capitalized at cost less accumulated depreciation incompliance with the requirements of BAS 16: Property, Plant and Equipment. The cost ofacquisition of an asset comprises its purchase price and any directly attributable cost ofbringing the assets to its working condition for its intended use inclusive of inward freight,duties and non-refunded taxes.

Fixed Asssets as on 01.07.20'13 3,199,763,49OAddition during the year 16,915,235IotalAssets 3,2L6,678,7t5Less: Accumutated ueprectatton as on 31.03.2tr?[ 784,455,526llVritten Down Value as on 31.03.2014 2,432,223,199

4.fi) lnventories:lnventories are carried at the lower of cost and net realizable value as prescribed by BAS2: lnventories. Cost determined on weighted average cost basis. The cost of inventoriescomprises of expenditure in the normal course of business in bringing the inventories totheir present location and condition. Net realizable value is based on estimated sellingprice less any further costs expected to be incurred to make the sale

4.01 Closing Stock

Raw MaterialsWork-in-Process

Finished Goods

Packing Materials

Literatule & Promotional MaterialsLaboratory Chemicals

Stock of Stattionery

.spares & Accessories

Balance as on 31st March,2014

286,249,3L9

38,448,253531,4L3,785

7L,028,7!2!8,657,92222,616,568

5,472,4t117,805,956

99L,691,927

e,+ 6,===r?.

Page 6: A Company With Global Vision - Beacon Pharmaceuticals Limited€¦ · Created Date 6/1/2016 3:42:42 PM

S.tiG ilaash and Gash Equivalents:

Cash and Cash equivalents includes cash in hand and with banks on current and depositaccounts which are held and available for use by the company without any restriction.There is insignificant risk of change in value of the same.

5.01 Gash and Gash Equivalents:Cash in hand

Cash at Bank

TotalCash and Cash Equivalents:

O,-l -zCompany'Secgdtalf

3,43L,842L,L94,566

'4,626,409

6^.^-d,Managing Director